Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$11.71 USD
-0.28 (-2.34%)
Updated May 15, 2024 04:00 PM ET
After-Market: $11.71 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 101 - 120 ( 157 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Unexpected Black Friday Deal Raises Questions; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology - SAGE, BIIB Enter Collaboration Deal
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Relatively Quiet Quarter of Execution as Key Zuranolone Readout Approach in 2021; Reiterate Neutral, PT up to $81
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
We See 2021 As A Critical Year; All Efforts On Track
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Interim SHORELINE Data Points in the Right Direction; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
How Long - SHORELINE Attempts To Answer The Question
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Key Takeaways from Sage FutureCast; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Upgrading to Outperform; See Reason For Optimism On Exposure
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
What Does the FutureCast Hold for SAGE? R-D Day Preview
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zuranolone Studies Ramp-Up, While Zulresso Continues to Experience Slow Sales; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
It''s All About the Pipeline as Covid-19 Strikes Another Blow to Zulresso; Reiterate Neutral, Target to $76
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Moving to Neutral; We See Zuranolone As Active, But Valuation Stretched
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Don''t Sleep on New Mechanisms for MDD: A Look at GABA Modulation and Orexin-2 Antagonists
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D